RE:RE:RE:Estimates ...MrMugsy wrote: wofats wrote: These are the actual numbers from quarter 3 .
The low estimates that are out there do not make sense
Over 50% of the EBITDA is from the last quarter.
Is the last quarter slow usually?
- Revenues were $73,340,
- Gross margin of $37,766
- Adjusted EBITDA1 was $17,334,
I don't know if we can say anything specific about the last quarter characteristics.
We had a Q4 where inventories were being replenished (2019?).
Don't think they are expecting that this time around.
Also - analysts were expecting a reduction in covid-related use for some of our products - based on what Samira was saying. Not sure how that's going to play out.
Will see !
Yes, I would hate to be a GUD analyst and having to estimate Q4 results. There will probably be a time when quarterly sales are easier to estimate, but for now... inventory, covid, launch-phase products, sales people returning to normal, treatments returning to normal, fund investments... impossible to say how all of these combined will affect one specific quarter.
As shareholders, all we can do is trust that they'll keep making intelligent decisions through whatever market conditions.